Dr Tan Min-Han (far left), founder and chief executive of Lucence, with members of the company's laboratory team in Singapore. He said Lucence conducts and processes the results of non-invasive tests on late-stage cancer patients using the company's patented sequencing test known as LiquidHallmark.
Caption: 
Dr Tan Min-Han (far left), founder and chief executive of Lucence, with members of the company's laboratory team in Singapore. He said Lucence conducts and processes the results of non-invasive tests on late-stage cancer patients using the company's patented sequencing test known as LiquidHallmark.